To validate the Akt-MIAT-miR-16-TGF-β2 pathway in vivo, we treated C57 mice with hepatic fibrosis with an AKT inhibitor, MK2206, to analyze the effect of Akt on downstream MIAT and TGF-β2 gene expression in HSCs. This evidence concerns the gene TGFB2 and Hepatic fibrosis.